Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Otenabant in Overweight Subjects with Type 2 Diabetes
NCT00391196Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Nov 2006
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of otenabant in obesity and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Pfizer. Primary endpoint: Percent change in body weight from baseline at 1 year. Started Nov 2006; status: terminated.
02
Drugs
otenabant
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00391196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00391196.